EXECUTIVE ENGAGEMENTS
OUTREACH
8432
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1182
Interactions with Platform & by Email
PARTICIPANTS
253
Unique # Participated
VALIDATIONS
114
Responses Validated*
COMPETITORS
38
Responses Validated*
BRANDS
0
Responses Validated*
* Login for a full stack data experience
DATE
JUL 2020
TABLES
60
PAGES
128
EDITION
7
PRICE
USD $4950
HIGHLIGHTS
Amid the COVID-19 crisis, the global market for Lifestyle Drugs estimated at US$30.7 Billion in the year 2020, is projected to reach a revised size of US$37.2 Billion by 2027, growing at a CAGR of 2.8% over the analysis period 2020-2027. Depression, one of the segments analyzed in the report, is projected to record a 2.4% CAGR and reach US$8.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Dermatology segment is readjusted to a revised 2.6% CAGR for the next 7-year period.
The Lifestyle Drugs market in the U.S. is estimated at US$9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.7 Billion by the year 2027 trailing a CAGR of 2.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR.
In the global Sexual Dysfunction segment, USA, Canada, Japan, China and Europe will drive the 2.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$2.8 Billion in the year 2020 will reach a projected size of US$3.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$4.2 Billion by the year 2027.We bring years of research experience to this 7th edition of our report. The 128-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
SELECT PLAYERS
Alembic Pharmaceuticals Limited; Amgen, Inc.; AstraZeneca PLC; Biocon Ltd.; Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; Eli Lilly and Company; GlaxoSmithKline PLC; Johnson & Johnson; Lupin Ltd.; Merck & Co., Inc.; Mylan Pharmaceuticals, Inc.; Novo Nordisk A/S; Pfizer, Inc.; Piramal Enterprises Limited; Procter & Gamble Company, The; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Zydus Cadila
SEGMENTS
» Therapy Area (Depression, Dermatology, Sexual Dysfunction, Obesity)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Global Competitor Market Shares |
| Lifestyle Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2025 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| Lifestyle Drugs Global Market Estimates and Forecasts in US$ Million by Region/Country: 2020-2027 |
| Lifestyle Drugs Global Retrospective Market Scenario in US$ Million by Region/Country: 2012-2019 |
| Lifestyle Drugs Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027 |
| Depression (Therapy Area) World Market by Region/Country in US$ Million: 2020 to 2027 |
| Depression (Therapy Area) Historic Market Analysis by Region/Country in US$ Million: 2012 to 2019 |
| Depression (Therapy Area) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027 |
| Dermatology (Therapy Area) Potential Growth Markets Worldwide in US$ Million: 2020 to 2027 |
| Dermatology (Therapy Area) Historic Market Perspective by Region/Country in US$ Million: 2012 to 2019 |
| Dermatology (Therapy Area) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027 |
| Sexual Dysfunction (Therapy Area) Geographic Market Spread Worldwide in US$ Million: 2020 to 2027 |
| Sexual Dysfunction (Therapy Area) Region Wise Breakdown of Global Historic Demand in US$ Million: 2012 to 2019 |
| Sexual Dysfunction (Therapy Area) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027 |
| Obesity (Therapy Area) World Market Estimates and Forecasts by Region/Country in US$ Million: 2020 to 2027 |
| Obesity (Therapy Area) Market Historic Review by Region/Country in US$ Million: 2012 to 2019 |
| Obesity (Therapy Area) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| UNITED STATES |
| Market Facts & Figures |
| US Lifestyle Drugs Market Share (in %) by Company: 2019 & 2025 |
| United States Lifestyle Drugs Market Estimates and Projections in US$ Million by Therapy Area: 2020 to 2027 |
| Lifestyle Drugs Market in the United States by Therapy Area: A Historic Review in US$ Million for 2012-2019 |
| United States Lifestyle Drugs Market Share Breakdown by Therapy Area: 2012 VS 2020 VS 2027 |
| CANADA |
| Canadian Lifestyle Drugs Market Estimates and Forecasts in US$ Million by Therapy Area: 2020 to 2027 |
| Canadian Lifestyle Drugs Historic Market Review by Therapy Area in US$ Million: 2012-2019 |
| Lifestyle Drugs Market in Canada: Percentage Share Breakdown of Sales by Therapy Area for 2012, 2020, and 2027 |
| JAPAN |
| Japanese Market for Lifestyle Drugs: Annual Sales Estimates and Projections in US$ Million by Therapy Area for the Period 2020-2027 |
| Lifestyle Drugs Market in Japan: Historic Sales Analysis in US$ Million by Therapy Area for the Period 2012-2019 |
| Japanese Lifestyle Drugs Market Share Analysis by Therapy Area: 2012 VS 2020 VS 2027 |
| CHINA |
| Chinese Lifestyle Drugs Market Growth Prospects in US$ Million by Therapy Area for the Period 2020-2027 |
| Lifestyle Drugs Historic Market Analysis in China in US$ Million by Therapy Area: 2012-2019 |
| Chinese Lifestyle Drugs Market by Therapy Area: Percentage Breakdown of Sales for 2012, 2020, and 2027 |
| EUROPE |
| Market Facts & Figures |
| European Lifestyle Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025 |
| European Lifestyle Drugs Market Demand Scenario in US$ Million by Region/Country: 2020-2027 |
| Lifestyle Drugs Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2012-2019 |
| European Lifestyle Drugs Market Share Shift by Region/Country: 2012 VS 2020 VS 2027 |
| European Lifestyle Drugs Market Estimates and Forecasts in US$ Million by Therapy Area: 2020-2027 |
| Lifestyle Drugs Market in Europe in US$ Million by Therapy Area: A Historic Review for the Period 2012-2019 |
| European Lifestyle Drugs Market Share Breakdown by Therapy Area: 2012 VS 2020 VS 2027 |
| FRANCE |
| Lifestyle Drugs Market in France by Therapy Area: Estimates and Projections in US$ Million for the Period 2020-2027 |
| French Lifestyle Drugs Historic Market Scenario in US$ Million by Therapy Area: 2012-2019 |
| French Lifestyle Drugs Market Share Analysis by Therapy Area: 2012 VS 2020 VS 2027 |
| GERMANY |
| Lifestyle Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Therapy Area for the Period 2020-2027 |
| German Lifestyle Drugs Historic Market Analysis in US$ Million by Therapy Area: 2012-2019 |
| German Lifestyle Drugs Market Share Breakdown by Therapy Area: 2012 VS 2020 VS 2027 |
| ITALY |
| Italian Lifestyle Drugs Market Growth Prospects in US$ Million by Therapy Area for the Period 2020-2027 |
| Lifestyle Drugs Historic Market Analysis in Italy in US$ Million by Therapy Area: 2012-2019 |
| Italian Lifestyle Drugs Market by Therapy Area: Percentage Breakdown of Sales for 2012, 2020, and 2027 |
| UNITED KINGDOM |
| United Kingdom Market for Lifestyle Drugs: Annual Sales Estimates and Projections in US$ Million by Therapy Area for the Period 2020-2027 |
| Lifestyle Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Million by Therapy Area for the Period 2012-2019 |
| United Kingdom Lifestyle Drugs Market Share Analysis by Therapy Area: 2012 VS 2020 VS 2027 |
| REST OF EUROPE |
| Rest of Europe Lifestyle Drugs Market Estimates and Forecasts in US$ Million by Therapy Area: 2020-2027 |
| Lifestyle Drugs Market in Rest of Europe in US$ Million by Therapy Area: A Historic Review for the Period 2012-2019 |
| Rest of Europe Lifestyle Drugs Market Share Breakdown by Therapy Area: 2012 VS 2020 VS 2027 |
| ASIA-PACIFIC |
| Lifestyle Drugs Market in Asia-Pacific by Therapy Area: Estimates and Projections in US$ Million for the Period 2020-2027 |
| Asia-Pacific Lifestyle Drugs Historic Market Scenario in US$ Million by Therapy Area: 2012-2019 |
| Asia-Pacific Lifestyle Drugs Market Share Analysis by Therapy Area: 2012 VS 2020 VS 2027 |
| REST OF WORLD |
| Rest of World Lifestyle Drugs Market Estimates and Forecasts in US$ Million by Therapy Area: 2020 to 2027 |
| Rest of World Lifestyle Drugs Historic Market Review by Therapy Area in US$ Million: 2012-2019 |
| Lifestyle Drugs Market in Rest of World: Percentage Share Breakdown of Sales by Therapy Area for 2012, 2020, and 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 38 |
| V. CURATED RESEARCH |
